macular degeneration

(redirected from Age Related Macular Degeneration)
Also found in: Dictionary, Thesaurus, Medical.

macular degeneration,

eye disorder causing loss of central vision. The affected area, the macula, lies at the back of the retina and is the part that produces the sharpest vision. The most serious visual impairment occurs when abnormal blood vessels form and leak serous fluid or bleed into the tissue of the macula, ultimately producing scar tissue. Peripheral (side) vision is unaffected. Onset may be acute with hemorrhage but usually is gradually progressive. Although some vision is retained, the ability to read, recognize faces, and drive a motor vehicle is greatly reduced. The condition is painless.

Macular degeneration is a major cause of vision impairment among elderly people. Although its underlying cause is unknown, it sometimes appears to run in families. Serious macular degeneraton, if diagnosed early, may have its progress stemmed by laser or photodynamic (cold laser and drug) treatment that closes leaking vessels. Antiangiogenic drugs, which inhibit the formation of new blood vessels, can be injected into the eye to stop degeneration and in some cases even improve vision. Sudden change in vision in someone over age 50 thus requires immediate medical attention.


See H. Grunwald, Twilight: Losing Sight, Gaining Insight (1999).

References in periodicals archive ?
A review of the Age Related Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
LiquiLens(TM) Intraocular lens for optical treatment of age related macular degeneration is synergistic with all of these products, and will provide the perfect adjunctive treatment.
The clinical trial is being conducted in patients with the neovascular or "wet" form of Age Related Macular Degeneration (wet AMD), a degenerative condition that is a major cause of severe vision impairment and blindness in adults over 55.
today announces that it has signed an exclusive agreement with The Johns Hopkins University Applied Physics Laboratory (APL), Laurel, Maryland, to license a patented method for the diagnosis and treatment of "wet" type Age Related Macular Degeneration (AMD) for the United States.